BIT Capital GmbH Purchases Shares of 12,743 MBX Biosciences, Inc. (NYSE:MBX)

BIT Capital GmbH acquired a new position in shares of MBX Biosciences, Inc. (NYSE:MBX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,743 shares of the company’s stock, valued at approximately $235,000.

Several other institutional investors also recently modified their holdings of the stock. Corebridge Financial Inc. bought a new stake in MBX Biosciences during the fourth quarter valued at approximately $103,000. JPMorgan Chase & Co. purchased a new stake in shares of MBX Biosciences during the 4th quarter valued at $168,000. Rhumbline Advisers bought a new stake in shares of MBX Biosciences during the 4th quarter worth $175,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in MBX Biosciences in the third quarter worth $278,000. Finally, Point72 Asset Management L.P. bought a new position in MBX Biosciences in the third quarter valued at $405,000.

MBX Biosciences Price Performance

Shares of MBX stock opened at $7.75 on Thursday. The business’s 50-day moving average price is $10.00. MBX Biosciences, Inc. has a 12-month low of $7.51 and a 12-month high of $27.50.

Insider Activity at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were purchased at an average cost of $10.69 per share, with a total value of $534,500.00. Following the completion of the purchase, the chief executive officer now owns 448,277 shares of the company’s stock, valued at $4,792,081.13. The trade was a 12.55 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carl L. Gordon acquired 143,170 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $10.84 per share, with a total value of $1,551,962.80. Following the completion of the acquisition, the director now owns 3,255,000 shares in the company, valued at approximately $35,284,200. The trade was a 4.60 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 240,672 shares of company stock valued at $2,555,308.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.